Log in | Jump |
Biomedical investment and business development chatter





Archives

This post was commissioned on June 6, 2008, and it was categorized as Uncategorized.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Highlights:

  • Inspire up on positive phase 3 results in a cystic fibrosis trial
  • Have a great weekend.


     

    Gainers (% price change) Last Trade Change Mkt Cap
    Inspire Pharmaceuticals, ISPH 5.19 +1.34 (34.81%) 293.66M
    MiddleBrook MBRK 3.85 +0.50 (14.93%) 215.63M
    Vision-Sciences, Inc. VSCI 5.50 +0.60 (12.24%) 193.97M
    Cardium Therapeutics Inc. CXM 2.39 +0.16 (7.13%) 104.22M
    Verenium Corporation VRNM 2.27 +0.14 (6.57%) 144.48M
    Losers (% price change)  
    ChemGenex Pharmaceuticals CXSP 14.50 -2.76 (-15.99%) 179.65M
    Sangamo Biosciences, Inc. SGMO 9.45 -1.60 (-14.48%) 385.71M
    Sucampo Pharmaceuticals, SCMP 10.23 -1.18 (-10.34%) 426.94M
    Alphatec Holdings, Inc. ATEC 4.52 -0.47 (-9.42%) 214.26M
    DURECT Corporation DRRX 4.40 -0.45 (-9.28%) 326.24M
    Most Actives (dollar volume)  
    Pfizer Inc. PFE 17.96 -0.71 (-3.80%) 121.50B
    Johnson & Johnson JNJ 65.76 -1.20 (-1.79%) 185.32B
    Merck & Co., Inc. MRK 37.49 -1.40 (-3.60%) 80.47B
    Wyeth WYE 42.93 -1.57 (-3.53%) 57.24B
    Eli Lilly & Co. LLY 48.42 -1.04 (-2.10%) 55.05B

    Theoretically Related Posts

    This post was constructed by .

    Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

    If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
    _blank _blank _blank _blank _blank _blank _blank

    Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

     

    Trackbacks

    (Trackback URL)

    close Reblog this comment
    blog comments powered by Disqus